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The remarkable pro-apoptotic properties of tumour necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) have led to considerable interest
in this protein as a potential anticancer therapeutic. However, TRAIL is
largely ineffective in inducing apoptosis in certain cancer cells, and the
mechanisms underlying this selectivity are unknown. In colon adenocarci-
nomas, posttranslational modifications including O- and N- glycosylation
of death receptors were found to correlate with TRAIL-induced apoptosis.
Additionally, mRNA levels of fucosyltransferase 3 (FUT3) and 6 (FUT6)
were found to be high in the TRAIL-sensitive colon adenocarcinoma cell
line COLO 205. In this study, we use agonistic receptor-specific TRAIL
variants to dissect the contribution of FUT3 and FUT6-mediated fucosyla-
tion to TRAIL-induced apoptosis via its two death receptors, DR4 and
DR5. Triggering of apoptosis by TRAIL revealed that the low FUT3/
6-expressing cells DLD-1 and HCT 116 are insensitive to DR5 but not to
DR4-mediated apoptosis. By contrast, efficient apoptosis is mediated via
both receptors in high FUT3/6-expressing COLO 205 cells. The reconstitu-
tion of FUT3/6 expression in DR5-resistant cells completely restored
TRAIL sensitivity via this receptor, while only marginally enhancing apop-
tosis via DR4 at lower TRAIL concentrations. Interestingly, we observed
that induction of the salvage pathway by external administration of
L-fucose restores DR5-mediated apoptosis in both DLD-1 and HCT 116
cells. Finally, we show that fucosylation influences the ligand-independent
receptor association that leads to increased death inducing signalling com-
plex (DISC) formation and caspase-8 activation. Taken together, these
results provide evidence for the differential impact of fucosylation on sig-
nalling via DR4 or DR5. These findings provide novel opportunities to
enhance TRAIL sensitivity in colon adenocarcinoma cells that are highly
resistant to DR5-mediated apoptosis.
Introduction
Colorectal cancer is the third most commonly diag-
nosed cancer in males and the second in females as
estimated by the International Agency for Research on
Cancer in 2018 [1]. Although early detection methods,
increased awareness and improved treatment
modalities have led to a reduction in both incidence
and cancer death rates in several western countries,
colorectal neoplasia are still one of the most deadly
cancers, causing around 880 000 deaths worldwide
every year [1]. The 5-year survival rate of colorectal
Abbreviations
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cancer patients for localized-stage is 90%, but
decreases to 71% and 14% for regional and distant
stage, respectively [2], although some relatively new
strategies are developed to predict surgical resection
more accurately such as ‘watch and wait’ strategy and
Narrow-band Imaging International Colorectal Endo-
scopic Classification (NICE) [3,4]. Thus, novel thera-
pies are required to improve the prognosis of
colorectal cancer patients.
The TNF superfamily member TRAIL has gathered
considerable attention as a potential cancer therapeutic,
as it is able to induce apoptosis selectively in tumour
cells while leaving normal cells unharmed [5–7]. TRAIL
is capable of signalling via two apoptosis-inducing
transmembrane death receptors (DRs), named DR4
(TRAIL-R1) and DR5 (TRAIL-R2). TRAIL also
binds to three decoy receptors: DcR1 (TRAIL-R3),
DcR2 (TRAIL-R4) and the soluble decoy receptor
osteoprotegerin (OPG) [8,9]. Decoy receptors are
unable to transduce death-inducing signals as they lack
a functional intracellular death domain (DD) [9–12],
and they can diminish apoptosis activation by compet-
ing with TRAIL-DR interactions [10,13] or by forming
nonsignalling heterotrimeric complexes [14].
Binding of trimeric recombinant human TRAIL
(rhTRAIL) to death receptors triggers the intracellu-
lar formation of the so-called death inducing sig-
nalling complex (DISC), consisting of Fas-associated
death domain (FADD), which further recruits and
activates pro-caspase-8 and/or pro-caspase-10 [15–18].
The activation of initiator caspases leads to direct
cleavage and activation of executioner caspases-3 and
-7 and subsequent apoptosis induction through the
extrinsic apoptotic pathway [19–22]. Activated cas-
pases also lead to the cleavage of Bid (tBid), resulting
in the release of mitochondrial factors, cleavage of
caspase-9 and activation of effector caspases leading
to apoptosis via the intrinsic pathway [23]. Despite its
reported tumour selective properties, several studies
showed that approximately 50% of the colorectal
cancer cell lines are resistant to rhTRAIL [24,25].
Untagged soluble human TRAIL Dulanermin devel-
oped for clinical use was shown to have a half-life of
only 23–31 min in nonhuman primates in preclinical
tests, which was attributed to its low mass [26]. In
order to improve half-life some TRAIL-R1/R2 ago-
nist antibodies have been developed, which have a
higher mass and therefore a prolonged half-life. How-
ever, Mapatumumab (HGS-ETR1), TRAIL-R1 ago-
nistic antibody, in Phase II clinical trial did not show
satisfactory activity with refractory colorectal cancer
patients [27]. This was shown due to the resistance of
colorectal cancer cell lines to TRAIL [24,25,28]. The
current focus is to use the combination strategies to
overcome TRAIL resistance. One Phase Ib open-
labelled clinical study (NCT00671372) reported that
the combination of Dulanermin and FOLFIRI
greatly prolonged the patient’s survival [29]. The
TRAIL-R2 agonistic antibody, Conatumumab
(AMG655) has been shown to be well-tolerated
(NCT00819169) in various cancers including advanced
colorectal cancer [30]. This clinical study is now con-
tinued to Phase II in combination with chemothera-
peutic agents (NCT01327612).
Fucosylation is an important type of posttransla-
tional modification in colon cancer [31], in which
fucose residues are terminally attached to N- or O-
linked glycans or glycolipids [32,33]. This modification
on the cell-surface is essential in numerous biological
processes, such as ontogeny, cellular differentiation
and signalling events [32,34]. All fucosyltransferases
require the donor substrate GDP-fucose, which can be
synthesized from GDP-mannose by the dominant
de novo pathway or from free L-fucose by the salvage
pathway [31,33,34]. In the past years, several reports
have described the importance of fucosylation in
TRAIL-induced apoptosis in colon cancer. Wagner
et al. [24] firstly described the positive correlation
between TRAIL sensitivity and mRNA levels of fuco-
syltransferase enzymes FUT3 and FUT6 in a panel of
colon adenocarcinoma cells. Furthermore, mutation of
the GDP-mannose-4,6-dehydratase (GMDS) gene leads
to the inactivation of the de novo GDP-fucose pathway
and decreased TRAIL sensitivity, resulting in acceler-
ated tumour growth in vivo, due to a lack of NK cell-
mediated tumour surveillance [23]. GMDS also plays
an important role in the formation of the FADD-
dependent complex II, which comprises FADD, cas-
pase-8 and c-FLIP. GMDS deficiency inhibited both
DR4- and DR5-mediated apoptosis by inhibiting the
formation of the complex II, while it did not affect for-
mation of the DISC or recruitment to and activation
of caspase-8 [35]. The same group showed that fucosy-
lation could be regulated through DNA methylation.
Treatment with the novel methyltransferase inhibitor
Zebularine was found to increase fucosylation levels,
leading to enhanced TRAIL-induced apoptosis without
increasing TRAIL receptor and/or caspase-8 levels
[36]. However, it is still unclear whether the fucosyla-
tion of DR4 and DR5 equally contributes to TRAIL-
mediated apoptosis. Recently receptor specific agonists
developed by us in the past have been used to unravel
the respective contribution of DR4 and DR5 N-glyco-
sylation on TRAIL signalling [37,38].
Here we investigated the more precise role of fuco-
sylation on DR4- and DR5-mediated apoptosis in
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colon adenocarcinomas, using TRAIL receptor-specific
apoptosis-inducing variants that bind selectively and
with high affinity to either DR4 or DR5 [38–42]. We
show that fucosylation of DR4 and DR5, either via
the salvage or via the de novo synthesis pathway,
enhances TRAIL signalling in colon adenocarcinoma
cells. We were able to increase DR5-mediated apopto-
sis in DR5 resistant colon cancer cell lines by improv-
ing the fucosylation status of the death receptor.
Results
Variation in sensitivity to DR4- and DR5-
mediated apoptosis among different colon
adenocarcinomas
To identify the sensitivity of colon adenocarcinoma
cells to TRAIL via either DR4 or DR5, we investigated
three cell lines: COLO 205, DLD-1 and HCT 116. By
detecting the Annexin V levels induced by WT TRAIL,
the DR4-specific TRAIL variant 4C7 and the DR5-spe-
cific TRAIL variant DHER, we found that COLO 205
was highly sensitive to TRAIL-mediated cell death via
both death receptors (Fig. 1A). Cell death induction in
DLD-1 and HCT 116 cells is primarily mediated by
DR4 and not by DR5 as evidenced by the high
Annexin V levels seen upon incubation with 4C7 but
not DHER (Fig. 1B,C). We next used flow cytometry
to determine if differences in surface expression of
death receptors can explain the differential TRAIL sen-
sitivity observed. We found that all three cell lines
express DR5 to a similar extend (Fig. 1D). These
results reinforce the notion that death receptor expres-
sion alone is not predictive of TRAIL susceptibility.
Inhibition of O-glycosylation leads to loss of
fucosylation resulting in a decrease in TRAIL
sensitivity
A role for fucosylation in TRAIL-induced apoptosis
of colon adenocarcinomas has been previously impli-
cated [24,35,36,43]. Wagner et al. tested a panel of 36
colorectal adenocarcinoma cell lines and found that
the sensitivity to TRAIL correlated with increased
mRNA levels of the O-glycosylation initiating enzyme
GALNT3, as well as the O-glycan processing
Fig. 1. Different colon adenocarcinoma cell lines exhibit differential sensitivities via DR4 and DR5. Apoptosis inducing potential of rhTRAIL
WT, 4C7 and DHER (0.05–500 ngmL1) in COLO 205 (A), DLD-1 (B) and HCT 116 (C) was determined after 16 h treatment using Annexin
V-APC by flow cytometry. Cell surface expression of TRAIL receptors was determined in COLO 205, DLD-1 and HCT 116 cells using flow
cytometry analysis and depicted as the Mean Fluorescence Intensity (MFI) ratio (D) and as FACS histograms compared to the binding of
isotype antibody (E). The values shown are mean  SD of three independent experiments.
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fucosyltransferase enzymes FUT3 and FUT6 [24].
However, they did not report the effect of inhibiting of
glycosylation on the different death receptors (DR4 or
DR5). Here we show that cell death induction via both
DR4 and DR5 is hampered in COLO 205 upon pre-
treatment with the pan O-glycosylation enzyme inhibi-
tor benzyl 2-acetamido-2-deoxy- a-D-galactopyranoside
(bGalNAc) (Fig. 2A). In DR4-sensitive HCT 116 cells,
cell death induced by 4C7 was also significantly
decreased after bGalNAc treatment (Fig. 2B). We
have not detected changes in the level of cell death in
the DR4/5-resistant human fibroblasts or in HCT 116
cells induced with DR5-specific rhTRAIL DHER
(Fig. 2C). These results substantiate for both death
receptors the importance of O-glycosylation and suc-
cessive fucosylation for becoming sensitive to TRAIL-
induced cell death.
Inhibition of fucosylation by adding 2F-peracetyl-
fucose decreases sensitivity to DR5 specific
TRAIL
In order to investigate further the effect of fucosyla-
tion on TRAIL-induced apoptosis, we chose a fuco-
sylation inhibitor to probe this effect in a cellular
setting. Although most inhibitors only work in vitro
[44], Rillahan et al. [45] showed that 2F-peracetyl-
fucose (2FF) is cell permeable and can be used
in vivo. We firstly examined the fucosylated oligosac-
charides from DLD-1 cells by blotting with recombi-
nant biotinylated Aleuria aurantia lectin (AAL) which
specifically binds to fucose [46,47]. Figure 3A shows
that the fucosylation level in DLD-1 cells reduced
only after treatment with the high concentration of
2FF, which is in line with the observations from Ril-
lahan et al. [45]. Subsequently, we performed viability
assays to explore alterations in the sensitivity of
DLD-1 cells to rhTRAIL WT and DHER after add-
ing 2FF. DLD-1 cells were firstly treated with 2FF
for 3 or 5 days, followed by 24 h incubation with
rhTRAIL WT or DHER. It can be seen from
Fig. 3B that cell survival increased after incubating
with the fucosylation inhibitor indicating that down-
regulation of fucosylation renders the receptor less
sensitive for rhTRAIL WT and DHER. This
decreased cell death induced by rhTRAIL DHER
was further confirmed by flow cytometric analysis
detecting apoptosis using the Violet Ratiometric
Membrane Asymmetry Probe. Figure 3C shows that
frequency of early apoptotic cells decreased after pre-
treatment with 500 lM of 2FF, which means that low
fucosylation levels lead to a reduction in rhTRAIL
DHER-induced apoptosis.
Triggering the fucosylation salvage pathway by
L-fucose improves TRAIL sensitivity
Fucosylation is an important type of posttranslational
modification in colon cancer [31] and fucosyltrans-
ferase enzyme levels are important determinants.
Fig. 2. Inhibition of O-glycosylation decreases TRAIL sensitivity.
COLO 205 (A), HCT 116 (B) and fibroblasts (C) were pretreated
with 2 mM bGalNAc for 24 h, after which cells were stimulated
with 1–1000 ngmL1 rhTRAIL 4C7 or DHER for 16 h. Cell death
levels were determined by MTS assay. The values shown are
mean  SD of three independent experiments. P value was
analysed by one-way ANOVA in Turkey’s multiple comparison with
GRAPHPAD PRISM version 5.00. **P < 0.005 and ***P < 0.0005.
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However, the presence of the donor substrate GDP-
fucose is equally important. Therefore, we reasoned
that targeting the de novo pathway or inducing the sal-
vage pathway by increasing the level of GDP-fucose
donor might enhance fucosylation and subsequently
trigger TRAIL-mediated apoptosis. Recently, Mori-
waki et al. [35] showed that HCT 116 cells are less
able to synthesize GDP-fucose, due to mutations in
the GMDS gene that plays a critical role in the de novo
GDP-fucose pathway. We therefore investigated
whether the salvage pathway can be activated by the
addition of L-fucose, and thereby potentially sensitize
these cells to TRAIL-induced cell death. To do this,
COLO 205, DLD-1, HCT 116, SW948 and WiDr cells
Fig. 3. Inhibition of fucosylation by adding 2F-peracetyl-fucose decreases sensitivity to DR5 specific TRAIL. (A) Proteins were blotted by
recombinant biotinylated AAL and probed again by b-actin as loading control. (B) Cell survival was measured and analysed by MTS assay.
The values shown are mean  SD of three independent experiments. (C) Cells were incubated with 2FF for 3 days and followed by adding
100 ngmL1 rhTRAIL DHER for 24 h. Apoptotic cells were stained by Violet Ratiometric Membrane Asymmetry Probe and measured by
LSR-II. L stands for living cells, A stands for apoptotic cells.
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were preincubated with L-fucose and after 24 h further
treated with rhTRAIL WT, 4C7 or DHER for 16 h
(0.05–500 ngmL1). The results show that the induc-
tion of DR5-mediated cell death is clearly enhanced
upon pretreatment with L-fucose in DR5 resistant cell
lines DLD-1, HCT 116, SW948 and WiDr (Fig. 4B–
E), with rhTRAIL DHER activities going up between
5 and 10 times in the presence of L-fucose. In contrast
to DHER sensitive COLO 205 cells, we only detected
a slight enhancement of TRAIL-induced cell death
using rhTRAIL DHER at low concentration
(0.05 ngmL1) after L-fucose pretreatment (Fig. 4A).
Since COLO 205, DLD-1 and HCT 116 are already
quite sensitive to 4C7, it is conceivable that it is diffi-
cult to increase the cell death at relative high concen-
tration (50 or 500 ngmL1). However, enhanced cell
death was observed in COLO 205 cells after treatment
with low concentration 4C7 (Fig. 4A). The response to
rhTRAIL WT was increased to an intermediate level
in the presence of L-fucose reflecting its signalling via
both DR4 and DR5. Enhanced cell death was not due
to changed expression levels of DR4 and/or DR5
receptors (Fig. 5A), neither due to the treatment by L-
fucose alone (Fig. 5B).
Taken together, these results indicate that L-fucose
sensitizes DLD-1, HCT 116, SW948 and WiDr to cell
death through the activation of mainly DR5.
Stable and transient overexpression of FUT3 and
FUT6 enhances TRAIL sensitivity via both death
receptors
Our previous data show that upregulation of fucosyla-
tion by the salvage pathway indeed improves the sensi-
tivity to TRAIL. Next, we focused on the two specific
fucosyltransferase enzymes FUT3 and FUT6, which
associate to TRAIL-sensitivity in colon cancer cells as
reported by Wagner et al. Quantitative PCR analysis
confirmed the low mRNA levels of FUT3 and FUT6
in our DR5-insensitive DLD-1 and HCT 116 cells
(Fig. 6A), which correlates with previous observations
[24]. We generated stable cell lines expressing either
FUT3 or FUT6 in both DLD-1 and HCT 116. Cells
were transduced either with an empty lentiviral vector
(CTRL) or a vector expressing FUT3 or FUT6 with a
GFP gene, allowing for the selection of transduced
cells. Using qRT-PCR a clear increase in relative
FUT3 or FUT6 mRNA levels was observed compared
to control with DLD-1 cells expressing higher levels of
FUT3 and FUT6 compared to HCT 116 (Fig. 6A).
Additional western blot analysis of FUT3 expression,
showed a significant increase in FUT3 protein levels in
both DLD-1:FUT3 and HCT 116:FUT3 cells, when
compared to control and FUT6 overexpressing cells
(Fig. 6B). FUT6 protein levels could not be analysed
with western blot due to the lack of suitable antibod-
ies. Flow cytometry analysis of transduced DLD-1 and
HCT 116 cells showed that overexpression of FUT3
and FUT6 did slightly change the expression of DR4
and DR5, but not to a level that explains the change
in sensitivity (Fig. 6C).
To evaluate the impact of FUT3 or FUT6 stable
overexpression on TRAIL-mediated apoptosis via
either DR4 or DR5, the transduced cells were treated
with 50 ngmL1 of the 4C7 or DHER, respectively.
Overexpression of either FUT3 or FUT6 dramatically
enhanced TRAIL-induced cell death via DR5 in both
DLD-1 and HCT 116 cells (Fig. 6D). The sensitivity
to rhTRAIL 4C7 in FUT3 or FUT6 overexpressing
DLD-1 cells only slightly improved, whereas cell death
remained largely unaltered in overexpressing HCT 116
cells (Fig. 6D). This is mainly due to the already high
cell death in control cells using 50 ngmL1 rhTRAIL
4C7. Interestingly at low concentrations (5 ngmL1),
where control DLD-1 cells show ~ 10% of killing with
rhTRAIL 4C7, transduced cells show an increase in
killing cells, indicating that only at lower concentra-
tions DR4-mediated cell death is slightly improved by
the overexpression of fucosyltransferases (Fig. 6E).
Moreover, to rule out the possibility that random inte-
gration of the gene into the genome itself could cause
the differential TRAIL sensitivity we repeated the sen-
sitivities assays with transient FUT3 and FUT6 over-
expressing DLD-1 cells. Overexpressing FUT3 show a
similar increase in TRAIL-induced cell death, which
indicates that the observations are robust (Fig. 7A).
Transient overexpression of FUT6 in both DLD-1 and
HCT 116 cells also enhanced the DR5 mediated cell
death as seen by Annexin V-APC staining (Fig. 7B).
In conclusion, FUT3 and FUT6 have a role in the
Fig. 4. L-fucose treatment augments TRAIL-induced apoptosis predominantly via the activation of DR5. COLO 205 (A), DLD-1 (B), HCT 116
(C), SW948 (D) and WiDr (E) cells were pretreated with 0 or 50 mM L-fucose for 24 h and subsequently incubated with 0.05–500 ngmL1
rhTRAIL WT, DHER or 4C7 for another 16 h. Cell death was assessed using MTS assay. Blue bars represent cells without adding L-fucose
and red bars represent cells pretreatment with 50 mM L-fucose. The values shown are mean  SD of three independent experiments. P
value was analysed by one-way ANOVA in Turkey’s multiple comparison with GRAPHPAD PRISM version 5.00. *P < 0.05, **P < 0.005 and
***P < 0.0005.
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regulation of TRAIL sensitivity via both death recep-
tors and are most important for DR5.
FUT3 and FUT6 overexpression leads to
preclustering of DR4 and DR5
Caspase-8 is very important in apoptotic signal trans-
duction via ligand-dependent receptor activation. For
TRAIL-mediated apoptosis, the signal is transmitted
into the pathway by the formation of the DISC,
which further recruits and activates caspase-8 [48]. To
investigate whether the observed higher levels of apop-
tosis in FUT3 overexpressing cells were mirrored in
the DISC formation, we co-immunoprecipitated the
DISC proteins using FLAG-rhTRAIL WT (FLAG-
WT) and FLAG-DHER, respectively. Caspase-8 acti-
vation was shown to be more pronounced in the
DISC in control and FUT3 overexpression cells when
immunoprecipitated with FLAG-WT and less by
FLAG-DHER (Fig. 8A). This is in line with the bind-
ing properties of FLAG-WT, which can trigger the
DISC formation via both DR4 and DR5, while
FLAG-DHER can do this only via DR5. Notably,
more DISC-associated caspase-8 was found in the S
and T clonal populations of the FUT3 overexpressing
cells as compared to the control cells, indicating that
the level of apoptotic signalling activation in the
FUT3 overexpressing cells is higher. We also show
that DR5 participating in the DISC formation is more
noticeable in the immunoprecipitates of FUT3 overex-
pressing cells, reinforcing the crucial response of DR5
to fucosylation (Fig. 8A). In a screen across a panel
of breast cancer cell lines, TRAIL-sensitive cells
showed more caspase-8 activity than TRAIL resistant
cells [49]. This has also been found in a subset of col-
orectal cancer cell lines [24]. In order to examine cas-
pase-8 and the downstream signal in more detail, we
analysed the pro-caspase-8, cleaved caspase-8 and
downstream PARP-1 activation. Western blot analysis
demonstrated that activation and cleavage of caspase-
8 and PARP-1 was more pronounced in FUT3 and
FUT6 overexpressing cells compared to control, which
confirms that the effect of fucosylation is transmitted
downstream in the apoptosis pathway (Fig. 8B).
Moreover, the amount of cleaved caspase-8 and
PARP-1 increased after the treatment with 4C7 and
DHER, which indicated that this upregulation of
fucosylation improved the DISC formation via both
death receptors. We therefore investigated whether
fucosylation enhanced TRAIL sensitivity by preclus-
tering of DR4 and DR5 on the cell surface using
immunofluorescent staining. Indeed, FUT3 and/or
FUT6 overexpressing cells showed more preclustering
of DR4 and DR5 compared to control cells (Fig. 8C).
These results confirm that fucosylation by FUT3 and
FUT6 overexpression enhances TRAIL-induced apop-
tosis through DISC formation by triggering the
preclustering of DR4 and DR5.
Discussion
Recent results have shown that glycosylation of death
receptors plays an important role in TRAIL-mediated
apoptosis. In particular, it was shown that O-glycosy-
lation increased TRAIL sensitivity by inducing effi-
cient DISC formation and caspase-8 activation
through the clustering of death receptors [24]. More-
over, the N-glycosylation via human DR4 and mouse
death receptor also regulates TRAIL-induced cell
death by the enhancing DISC formation [37]. The fact
that O- and N-glycosylation can undergo successive
posttranslational modification, such as fucosylation
and sialylation, implies that there might be a connec-
tion and an additive effect in relation to TRAIL sensi-
tivity [33,50]. Specifically, FUT3 and FUT6 expression
Fig. 5. Death receptor 4 and DR5 receptor expression and L-fucose
tolerance. (A) Cell surface expression of TRAIL receptors was
determined in DLD-1 and HCT 116 cells treated with 0 or 50 mM L-
fucose using flow cytometry analysis and expressed as the Mean
Fluorescence Intensity (MFI) ratio compared to the binding of
isotype antibody. The values shown are mean  SD of three
independent experiments. (B) HCT 116 cells were treated with 0,
50 or 100 mM L-fucose and cell death was measured by FACS
using Annexin V-FITC/PI staining.
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Fig. 6. Fucosyltransferase 3 and FUT6 overexpression enhances TRAIL sensitivity of DLD-1 and HCT 116 cells via both death receptors.
Overexpression of FUT3 and FUT6 was analysed by qRT-PCR of DLD-1 and HCT 116 cells transduced with control, FUT3 or FUT6
overexpressing plasmid. (A) The amount of FUT3 or FUT6 amplicon was relative to the endogenous reference RPL27 and normalized to the
control cells. (B) Western blot analysis of FUT3 expression in control or FUT3/6 transduced DLD-1 and HCT 116 cells, c-tubulin served as a
loading control. (C) The expression of DR4, DR5, DcR1 and DcR2 in control, FUT3 and FUT6 overexpressing DLD-1 and HCT 116 cells. Cell
death of transduced DLD-1 and HCT 116 cells overexpressing FUT3/6 was assessed after treatment with 50 ngmL1 rhTRAIL 4C7 or
DHER (D) or 5 ngmL1 rhTRAIL 4C7 or DHER (E) for 16 h as measured by MTS assay. The values shown are mean  SD of three
independent experiments. P value was analysed by one-way ANOVA in Turkey’s multiple comparison with GRAPHPAD PRISM version 5.00.
*P < 0.05, **P < 0.005 and ***P < 0.0005.
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was shown to correlate with TRAIL sensitivity in a
large panel of colorectal adenocarcinoma cell lines
[24]. Moreover, GMDS deficiency leading to a loss of
de novo fucosylation was found to increase tumour
growth and metastasis in vivo [35], due to a reduced
FADD-dependent complex II formation [43]. Here, we
provide for the first time evidence that signalling via
DR5 is for the major part responsible for this L-fucose
dependent apoptosis induction.
In this study, we observed that DLD-1 and HCT
116 cells are highly insensitive to DR5-mediated apop-
tosis in contrast to the colon adenocarcinoma COLO
205 cell line that shows a high sensitivity to both
DR4- and DR5-mediated apoptosis. Here we further
show that this insensitivity is not related to a lack of
surface expression levels of DR5, but to a specific lack
of fucosylation. This finding is in line with earlier
observations that TRAIL-sensitive colon adenocarci-
noma cell lines show relatively high mRNA levels of
FUT3 and FUT6, while the TRAIL-resistant cell lines,
such as DLD-1 and HCT 116, show low expression of
FUT3 and FUT6 [24,37]. Reduction in the number of
fucosyl attachment sites by pretreatment with the O-
glycosylation inhibitor bGalNAc led to decreased
TRAIL sensitivity via DR5 in all three cell lines
mentioned, as determined by us using TRAIL-death
receptor specific variants. The bGalNAc treatment also
had an effect on the DR4 sensitivity in HCT 116,
although there is a considerable residual activity. This
may be due to the fact that DR4, in contrast to DR5,
has N-glycosylation sites, which are not affected by
bGalNAc ensuing outstanding attachment sites for
fucose. This observed reduction in DR4 signalling is
slightly different from the data reported by Dufour
et al., in which they reported that DR4-induced apop-
tosis in another bone osteosarcoma cell line was not at
all affected by the bGalNAc treatment. This may be
due to the usage of a different cell line and/or the use
of a different DR4-specific variant [37]. Direct inhibi-
tion of fucosylation turned out to be complicated as
most reported inhibitors do not penetrate into the cell
and can be used only in vitro. By exploiting promiscu-
ous monosaccharide salvage pathways the inhibitor
2FF can be partly imported and metabolized in cells
[45] and we indeed could show inhibition of fucosyla-
tion in DLD-1 colon cancer cells using high concentra-
tions. The observation that the sensitivity to rhTRAIL
DHER in these cells is lowered, forms an additional
indication for the important role of fucosylation in
activating death receptor.
Fig. 7. TRAIL sensitivity of transient FUT3 or FUT6 transfected DLD-1 and HCT 116 cells. Transient FUT3 overexpressing DLD-1 cells were
treated with 5–500 ngmL1 rhTRAIL WT, 4C7 or DHER and cell death was measured by MTS assay (A). (B) Transient FUT6 overexpressing
cells lines DLD-1 and HCT 116 cells were treated with 50 ngmL1 rhTRAIL WT, 4C7 and DHER. Apoptosis induction was assessed after
16 h using Annexin V-APC staining measured by flow cytometry. The values shown are mean  SD of three independent experiments. P
value was analysed by one-way ANOVA in Turkey’s multiple comparison with GRAPHPAD PRISM version 5.00. **P < 0.005, ***P < 0.0005 and
****P < 0.00005.
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Without doubt, the most spectacular finding of our
study is the observation that the simple addition of L-
fucose re-sensitizes DLD-1 and HCT 116 cells to
DR5-mediated apoptosis and enhances the DHER
sensitivity from 5 to 40%. Interestingly, oral adminis-
tration of L-fucose was found to successfully increase
fucosylation in the patient with leukocyte adhesion
deficiency type II (LAD II), a rare inherited disorder
Fig. 8. Fucosyltransferase 3 and FUT6 overexpression leads to preclustering of DR4 and DR5. (A) Co-immunoprecipitation of the TRAIL
DISC. Two population of FUT3 overexpression cells (S and T) and control cells were stimulated by 1 lgmL1 FLAG-TRAIL WT or FLAG-
DHER respectively for 0 or 30 min. Then the DISC was immunoprecipitated with FLAG antibody. DR5 or cleaved caspase-8 from the DISC
were detected by immunoblot. (B) Western blot analysis of FUT3 or FUT6 transduced DLD-1 cells treated with 500 ngmL1 rhTRAIL WT,
4C7 or DHER for 1 h. Caspase-8 and PARP-1 activation was examined and analysed using densitometry (values depicted as % of total
protein); c-tubulin served as a loading control. The data are presented as mean values of three independent experiments. (C)
Immunostaining of DLD-1 cells transduced with control, FUT3 or FUT6 plasmids, containing the GFP gene. Cells were seeded on poly-L-
lysine coated coverslips and stained with primary antibodies against DR4 or DR5, and secondary antibody conjugated with Alexa Fluor 647.
Nuclei were counterstained with DAPI. The right graphs depict the quantification of the mean fluorescence intensity of 20 single confocal
pictures of each cell lines. P value was analysed by one-way ANOVA in Turkey’s multiple comparison with GRAPHPAD PRISM version 5.00.
*P < 0.05.
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of fucose metabolism [51–53]. Moreover, tumour
growth, mitotic activity and metastatic setting were
greatly suppressed by daily intraperitoneal injection of
L-fucose in the Ehrlich carcinoma mice [53]. Our
results further suggest that the sensitivity to TRAIL
can be simulated after elevated expression of FUT3 or
FUT6 in tumour cells, which is mainly mediated via
DR5 as evidenced by the enhanced sensitivity to
DHER of these cells.
Furthermore, mechanistic studies show that in
FUT3/6 overexpressing cells compared to control
cells, the preclustering of DR4 and/or DR5 is
enhanced without any increase in the level of receptor
expression. Moreover this clustering directly stimu-
lates more DISC formation and caspase-8 activation.
In agreement with the regulation by O- or N-glycosy-
lated death receptors, the upregulation of fucosylation
changes the distribution of death receptors and
enhances their clustering leading to enhanced apop-
totic signal transduction after the stimulation by
TRAIL [24,39]. There is some evidence showing that
a preligand assembly domain association (PLAD)
consisting of death receptors, especially DR5, and
decoy receptors lacking a death domain attenuates
TRAIL-induced apoptosis [14,54]. In concert with
this PLAD model, it can be conceived that if most
death receptors are involved in the preclustering
activity due to the upregulation of fucosylation, the
possibility for them to bind to the decoy receptors
greatly decreases. By this mechanism, TRAIL induced
apoptosis might become significantly improved upon
fucosylation.
Many examples have already shown the diagnostic
applications related to fucosylation. The most repre-
sentative type of cancer biomarker is fucosylated
alpha-fetoprotein (AFP) in hepatocellular carcinoma
(HCC). AFP with core fucosylation is very specific
in the early stage of HCC and widely used as diag-
nostic marker [55,56]. Kyselova et al. [57] measured
the glycan profile in serum and proposed eight
potential sialylated and fucosylated N-glycan struc-
tures to stage the progression of breast cancer.
Moreover, in the serum from patients with advanced
pancreatic cancer, haptoglobin fucosylation patterns
were found that differ from those at early stage [58].
Our results suggest that the status of fucosylation
indicates the sensitivity to DHER in colon carcinoma
and provides a potential biomarker for TRAIL ther-
apy. Taken together, our findings give a new insight
into the effect of posttranslational modification on
TRAIL-sensitivity and imply promising novel
approaches for restoring TRAIL response in resistant
cancer cells.
Materials and methods
Cell lines and reagents
Human colorectal cancer cell lines COLO 205, DLD-1,
HCT 116, SW948 and WiDr were cultured in RPMI1640
medium supplemented with 10% fetal bovine serum (FBS),
100 unitsmL1 Penicillin and 100 lgmL1 Streptomycin
in a humidified incubator at 37 °C containing 5% CO2.
Human foreskin fibroblasts (Cell Stock, University of
Groningen) were cultured in Ham’s F-10 medium supple-
mented with 10% fetal bovine serum (FBS), 100 uni-
tsmL1 Penicillin and 100 lgmL1 Streptomycin. All
materials mentioned above were obtained from Ther-
mofisher Scientific (Landsmeer, The Netherlands).
rhTRAIL wild-type (WT), the DR4-specific TRAIL variant
4C7 and the DR5-specific TRAIL variant DHER (amino
acids 114–281) were constructed and produced as previ-
ously described [37,38]. L-(-)-Fucose (L-fucose), benzyl
2-acetamido-2-deoxy-a-D-galactopyranoside (bGalNAc) and
2F-peracetyl-fucose (2FF) were purchased from Merck
(Darmstadt, Germany).
MTS assay
Cell viability and proliferation assays were conducted using
MTS assays. Cells were seeded in triplicate in 96-well plates
at a cell density of 10 000 cells/well in 0.1 mL medium.
After 24 h, cells were treated with concentrations ranging
from 0 to 500 ngmL1 of rhTRAIL WT, 4C7 or DHER
for 16 h, to a final volume of 0.15 mL. In the case of only
L-fucose treatment, cells were incubated with different con-
centrations of L-fucose (0–100 mM) for 48 h to a final vol-
ume of 0.2 mL. For the combination of L-fucose and
rhTRAIL, cells were preincubated with 0 or 50 mM of
L-fucose in a final volume of 0.15 mL. After 24 h, cells were
treated with concentrations ranging from 0 to 500 ngmL1
of rhTRAIL WT, 4C7 or DHER for 16 h to a final volume
of 0.2 mL. Stock solutions of L-fucose were serially diluted
in serum-free RPMI medium and TRAIL ligands in com-
plete medium. Cells were incubated with MTS reagent
according to manufacturer’s instructions (Promega, Leiden,
The Netherlands). Cell viability was determined by measur-
ing the absorption at 492 nm using a microplate reader
(Thermo Labsystems, Vasai, India). For inhibition of O-gly-
cosylation, cells were pretreated with 2 mM bGalNAc in a
final volume of 0.15 mL. After 24 h, cells were treated with
rhTRAIL concentrations, ranging from 0 to 1000 ngmL1
of rhTRAIL 4C7 or DHER for 16 h, to a final volume of
0.2 mL. For inhibition of fucosylation, cells were seeded at
the density of 1000 cells/well or 100 cells/well in 0.1 mL
medium and incubated with 2FF at indicated concentration
for 3 days and 5 days, respectively. Next, cells were treated
with rhTRAIL WT or DHER at indicated concentration
for 24 h.
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Apoptotic assay
Apoptosis induction was measured using Annexin V-APC
(IQP Products, Groningen, The Netherlands) staining and
quantified by flow cytometry. Cells were seeded in 6-well
plates 24 h prior to treatment. The next day, cells were incu-
bated with 0–500 ngmL1 rhTRAIL WT, 4C7 or DHER
for 16 h. After treatment, cells were harvested and washed
with calcium buffer (10.9 lM HEPES, 140 lM NaCl, 2.5 lM
CaCl2) (Merck). Cell pellets were resuspended in 60 lL cal-
cium buffer complemented with 5 lL Annexin V-APC and
incubated for 20 min on ice. Cells were washed and analysed
using a FACS Calibur flow cytometer (BD Biosciences). For
cells treated by 2FF, 3E5 cells were firstly seeded in one-well
of 6-well plates. Fifty micrometres or 500 lM 2FF was
added at the following day and incubated for 3 days. Three
days later, 100 ngmL1 rhTRAIL WT or DHER was
added for 24 h. After treatment, cells were harvested in PBS
and apoptotic cells were measured and analysed by LSR-II
(BD Biosciences) using the dead cell apoptotic kit from
Thermofisher Scientific (Violet Ratiometric Membrane
Asymmetry Probe, Landsmeer, the Netherlands).
TRAIL receptor membrane expression analysis
Cells were harvested and washed with FACS buffer (PBS
with 1% BSA). Cell surface expression of TRAIL receptors
was determined using 10 lgmL1 TRAIL-R1, TRAIL-R2,
TRAIL-R3, TRAIL-R4 (Alexis Biochemicals, Enzo Life
Sciences, Bruxelles, Belgium) or negative control mouse
IgG1 (Agilent, Santa Clara, CA, USA). Cells were incu-
bated with primary antibodies for 1 h on ice. Subsequently,
the cells were washed and incubated for 1 h with R-phy-
coerythrin (PE) conjugated goat anti-mouse antibody
(Southern Biotech, Birmingham, AL, USA) or Alexa Fluor
488 conjugated goat anti-mouse antibody (Thermofisher
Scientific). Receptor cell surface expression was analysed
using a FACS Calibur flow cytometer (BD Biosciences).
Transient overexpression of FUT6-GFP and
lentiviral overexpression of FUT3 and FUT6
For transient overexpression of FUT6-GFP, DLD-1 and
HCT 116 cells were seeded in 6-well plates at a density of
150 000 cells/well. The next day, the subconfluent cultures
were transfected with plasmid containing GFP-conjugated
a-1,3-fucosyltransferase 6, fuc-T6-GFP (FUT6-GFP) (a
kind gift from prof. Jack Rohrer) using the FuGENE HD
Transfection Reagent (Promega, Leiden, the Netherlands)
according to manufacturer’s instructions. Cells were seeded
48 h after transfection and treated with 50 ngmL1
rhTRAIL WT, 4C7 or DHER for 16 h. Cell death induc-
tion was measured using Annexin V-APC staining.
For lentiviral overexpression of FUT3 and FUT6,
pLenti-GIII-CMV-GFP-2A-Puro plasmids encoding FUT3
or FUT6 and the control plasmid were purchased from
Applied Biological Materials Inc. (Heidelberg, Germany).
For the packaging of the lentiviral particles, 2*106
HEK293 cells were plated in 94 mm cell culture dishes. The
following day, cells were transfected with either pLenti-
CMV-GFP vector expressing FUT3, FUT6 or the control
vector, using CaCl2. After 48 h, the medium containing
virus particles was harvested, filtered, mixed with Polybrene
(Merck) and added to DLD-1 and HCT 116 cells, which
were plated the day before at a density of 0.25*106 cells in
a 6-well plates; the final concentration of Polybrene was
10 lgmL1. The following day, the previous steps were
repeated, therefore cells were exposed to the viral particles
for 48 h in total. Mixed populations of control-, FUT3- or
FUT6-overexpressing cells were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum, 100
unitsmL1 Penicillin, 100 lgmL1 Streptomycin and
2 lgmL1 Puromycin (Merck) in a humidified incubator at
37 °C containing 5% CO2. Single clones that expressed
GFP were subcloned.
Quantitative real-time PCR
RNA was isolated from DLD-1 and HCT 116 cells trans-
duced with control, FUT3 or FUT6 lentiviral plasmids
using the RNeasy Mini Kit (QIAGEN, Venlo, the Nether-
lands) according to the manufacturer’s instructions. cDNA
was synthesized from 4 lg total RNA using oligo dT pri-
mers and M-MLV Reverse Transcriptase (Thermofisher
Scientific) in a total volume of 80 lL. Quantitative real-
time (qRT)-PCR was performed to determine the mRNA
expression levels of FUT3 (50- GGACATGGCCTTTCCAC
ATC-30 and 50-TCCAGGTGCTGGCAGTTAGG-30), FU
T6 (50-CGCTTCCCAGACAGCACAGG-30 and 50-TCCG
TCCATGGCTTTCAGCTGCCA-30) and the housekeeping
gene RPL27 (50-TCCGGACGCAAAGCTGTCATCG-30
and 50-TCTTGCCCATGGCAGCTGTCAC-30) using
SsoAdvanced Universal SYBR Green Supermix (BioRad,
Veenendaal, The Netherlands) on the CFX Connect Real-
Time PCR Detection System (Bio-Rad). The protocol was
as follows: initial denaturation at 98 °C for 3 min, followed
by 45 cycles of amplification (5 s at 98 °C and 20 s at
65 °C). Finally, a melting curve analysis was performed to
ensure that only a single PCR amplicon was produced.
Western blotting
Cells were harvested and lysed by using the Mammalian
Protein Extraction Reagent (Thermofisher Scientific) with
additional Protease Inhibitor Cocktail, EDTA-Free (Roche,
Basel, Switzerland). Protein concentrations were determined
using a Bradford assay (Bio-Rad). Equal amounts of pro-
tein (20 lg) for each sample were loaded per lane on pre-
cast 4–12% SDS-PAGE gels (Thermofisher Scientific) and
transferred onto Immobilon-FL PVDF 0.45 lm membranes
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(Merck). Subsequently, the membranes were blocked for
1 h at room temperature in blocking buffer (Rockland,
Limerick, USA). Western blot membranes were probed
overnight at 4 °C. The following primary antibodies were
used: Caspase-8 (Cell Signalling Technologies, Leiden, the
Netherlands), FUT3 (Abcam, Cambridge, UK) and PARP-
1 (Cell Signalling Technologies). Goat-a-mouse-IRDye 680
(LI-COR Biosciences, Lincoln, NE, USA) or goat-a-rabbit-
IRDye 800CW (LI-COR Biosciences) secondary antibodies
were used for detection using a LI-COR Odyssey Infrared
Imaging System (Badhomburg, Germany). Membranes
were probed with anti-c-tubulin (Merck) to confirm equal
loading. For AAL blot, after proteins were transferred
onto nitrocellulose membrane (Merck), this membrane was
blocked overnight in 3% BSA at 4 °C. Afterwards, mem-
brane was incubated with 0.5 lgmL1 of recombinant
biotinylated AAL (Vector lab, Peterborough, UK) for
30 min at room temperature. Streptavidin conjugated with
HRP (Thermofisher Scientific) used as secondary antibody
was added for 30 min at room temperature. At last, mem-
brane was detected using Pierce ECL kit (Thermofisher
Scientific). Anti-b-actin (Cell Signalling Technology) was
probed as relative loading control.
Co-immunoprecipitation of TRAIL-DISC complex
M-270 Epoxy beads (Thermofisher Scientific) were cova-
lently coupled with anti-FLAG antibody (Merck) according
to the manufacture’s instruction (5–7 lg per mg beads) at
37 °C for 20 h. The next day beads were washed and
stored following the protocol from the company. 3–
4 9 107 cells were harvested and incubated with 1 lgmL1
FLAG-rhTRAIL or FLAG-DHER in the complete med-
ium at 4 °C to prevent ligand receptor complex internaliza-
tion. After washing with PBS the cell pellet was weighted
and nine volumes of the extracting buffer A (Thermofisher
Scientific) supplemented with 50 mM NaCl and protease
inhibitor cocktail, were added and incubated on ice for
15 min. Cell lysate was cleared by centrifugation at 2600 g
for 5 min at 4 °C, then the DISC was co-immunoprecipi-
tated overnight with the prepared beads at 4 °C. Beads
were washed three times with the extraction buffer A and
one time with 1xLWB supplied with the kit; then the pro-
tein complex was eluted using SDS loading buffer (50 mM
Tris-HCl, pH 6.8, 2% SDS, 6% glycerol).
Immunostaining of surface DR4 and DR5
DLD-1:CTRL, DLD-1:FUT3 and DLD-1:FUT6 cells were
seeded at a density of 150 000 cells on Poly-L-lysine (Mer-
ck) coated coverslips. Cells were fixed using 4% formalde-
hyde solution (Merck) for 15 min at room temperature.
The cells were then stained for 1 h with 1 : 50 in PBS
diluted TRAIL-R1 (Alexis Biochemicals, Enzo Life
Sciences, Bruxelles, Belgium), DR5-01-1 (Exbio, Praha,
Czech republic) or IgG1 negative control (Agilent). After
washing with PBS three times, cells were incubated with
secondary antibody donkey anti-mouse IgG (H + L) Alexa
Fluor 647 (Jackson ImmunoResearch, Cambridge, UK) at
a concentration of 1 : 100 for 1 h. Nuclei were counter-
stained with 0.2 lgmL1 DAPI (Thermofisher Scientific)
for 10 min. The coverslips were mounted with CitiFluor
(Agar Scientific, Stansted, UK). Slides were photographed
using a Leica DMI 6000 inverted microscope.
Statistical analysis
Data were presented as mean  standard deviation (SD)
from three independent experiments. Comparisons between
groups were analysed by one-way ANOVA with GRAPHPAD
PRISM version 5.00 (GraphPad Software, San Diego, CA,
USA). Results were considered statistically significant at
5% level.
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